{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T13:18:05Z","timestamp":1791292685830,"version":"4.1.0"},"reference-count":35,"publisher":"EDP Sciences","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Sci (Paris)"],"published-print":{"date-parts":[[2005,12]]},"DOI":"10.1051\/medsci\/200521121054","type":"journal-article","created":{"date-parts":[[2011,11,28]],"date-time":"2011-11-28T08:48:39Z","timestamp":1322470119000},"page":"1054-1062","source":"Crossref","is-referenced-by-count":12,"title":["Anticorps humanis\u00e9s en th\u00e9rapeutique"],"prefix":"10.1051","volume":"21","author":[{"given":"Dominique","family":"Bellet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Dangles-Marie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"250","published-online":{"date-parts":[[2005,12,15]]},"reference":[{"key":"R1","doi-asserted-by":"crossref","unstructured":"Ehrlich P Herta CA, Shigas K. \u00dcber einige Verwendungen der Naphtochinosuflsaure.Z Physiol Chem1904; 61 : 379\u201392.","DOI":"10.1515\/bchm2.1904.41.5.379"},{"key":"R2","doi-asserted-by":"crossref","unstructured":"Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity.Nature1975; 256 : 495\u20137.","DOI":"10.1038\/256495a0"},{"key":"R3","doi-asserted-by":"crossref","unstructured":"Miller RA, Maloney DG, Warnke R, Levy R. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody.N Engl J Med1982; 306 : 517\u201322.","DOI":"10.1056\/NEJM198203043060906"},{"key":"R4","doi-asserted-by":"crossref","unstructured":"Hwang WY, Foote J. Immunogenicity of engineered antibodies.Methods2005; 36 : 3\u201310.","DOI":"10.1016\/j.ymeth.2005.01.001"},{"key":"R5","doi-asserted-by":"crossref","unstructured":"Qu Z, Griffiths GL, Wegener WA,et al.Development of humanized antibodies as cancer therapeutics.Methods2005; 36 : 84\u201395.","DOI":"10.1016\/j.ymeth.2005.01.008"},{"key":"R6","doi-asserted-by":"crossref","unstructured":"Morrison SL, Johnson MJ, Herzenberg LA, Oi VT. Chimeric human antibody molecules : mouse antigen-binding domains with human constant region domains.Proc Natl Acad SciUSA1984; 81 : 6851\u20135.","DOI":"10.1073\/pnas.81.21.6851"},{"key":"R7","doi-asserted-by":"crossref","unstructured":"Jones PT, Dear PH, Foote J,et al.Replacing the complementarity-determining regions in a human antibody with those from a mouse.Nature1986; 321 : 522\u20135.","DOI":"10.1038\/321522a0"},{"key":"R8","doi-asserted-by":"crossref","unstructured":"Tsurushita N, Hinton PR, Kumar S. Design of humanized antibodies : from anti-Tac to Zenapax.Methods2005; 36 : 69\u201383.","DOI":"10.1016\/j.ymeth.2005.01.007"},{"key":"R9","doi-asserted-by":"crossref","unstructured":"Tamura M, Milenic DE, Iwahashi M,et al.Structural correlates of an anticarcinoma antibody : identification of specificity-determining residues (SDRs) and development of a minimally immunogenic antibody variant by retention of SDRs only.J Immunol2000; 164 : 1432\u201341.","DOI":"10.4049\/jimmunol.164.3.1432"},{"key":"R10","doi-asserted-by":"crossref","unstructured":"Zhang W, Feng J, Li Y,et al.Humanization of an anti-human TNF-alpha antibody by variable region resurfacing with the aid of molecular modeling.Mol Immunol2005; 42 : 1445\u201351.","DOI":"10.1016\/j.molimm.2005.01.015"},{"key":"R11","doi-asserted-by":"crossref","unstructured":"Roguska MA, Pedersen JT, Keddy CA,et al.Humanization of murine monoclonal antibodies through variable domain resurfacing.Proc Natl Acad Sci USA1994; 91 : 969\u201373.","DOI":"10.1073\/pnas.91.3.969"},{"key":"R12","doi-asserted-by":"crossref","unstructured":"Padlan EA. A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties.Mol Immunol1991; 28 : 489\u201398.","DOI":"10.1016\/0161-5890(91)90163-E"},{"key":"R13","doi-asserted-by":"crossref","unstructured":"Houghton AN, Scheinberg DA. Monoclonal antibody therapies-a \u2019constant\u2019 threat to cancer.Nat Med2000; 6 : 373\u20134.","DOI":"10.1038\/74621"},{"key":"R14","unstructured":"Zum Buschenfelde CM, Hermann C, Schmidt B,et al.Antihuman epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab enhances cytolytic activity of class I-restricted HER2-specific T lymphocytes against HER2-overexpressing tumor cells.Cancer Res2002; 62 : 2244\u20137."},{"key":"R15","doi-asserted-by":"crossref","unstructured":"Slamon DJ, Leyland-Jones B, Shak S,et al.Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.N Engl J Med2001; 344 : 783\u201392.","DOI":"10.1056\/NEJM200103153441101"},{"key":"R16","doi-asserted-by":"crossref","unstructured":"Elkin EB, Weinstein MC, Winer EP,et al.HER-2 testing and trastuzumab therapy for metastatic breast cancer : a cost-effectiveness analysis.J Clin Oncol2004; 22 : 854\u201363.","DOI":"10.1200\/JCO.2004.04.158"},{"key":"R17","doi-asserted-by":"crossref","unstructured":"Ames SA, Gleeson CD, Kirkpatrick P. Omalizumab.Nat Rev Drug Discov2004; 3 : 199\u2013200.","DOI":"10.1038\/nrd1334"},{"key":"R18","doi-asserted-by":"crossref","unstructured":"Holgate ST, Djukanovic R, Casale T, Bousquet J. Anti-immunoglobulin E treatment with omalizumab in allergic diseases : an update on anti-inflammatory activity and clinical efficacy.Clin Exp Allergy2005; 35 : 408\u201316.","DOI":"10.1111\/j.1365-2222.2005.02191.x"},{"key":"R19","doi-asserted-by":"crossref","unstructured":"Yednock TA, Cannon C, Fritz LC,et al.Prevention of experimental autoimmune encephalomyelitis by antibodies against alph4 beta1 integrin.Nature1992; 356 : 63\u20136.","DOI":"10.1038\/356063a0"},{"key":"R20","doi-asserted-by":"crossref","unstructured":"Noseworthy JH, Kirkpatrick P. Natalizumab.Nat Rev Drug Discov2005; 4 : 101\u20132.","DOI":"10.1038\/nrd1637"},{"key":"R21","doi-asserted-by":"crossref","unstructured":"Miller DH, Khan OA, Sheremata WA,et al.A controlled trial of natalizumab for relapsing multiple sclerosis.N Engl J Med2003; 348 : 15\u201323.","DOI":"10.1056\/NEJMoa020696"},{"key":"R22","doi-asserted-by":"crossref","unstructured":"Van Assche G, Van Ranst M, Sciot R,et al.Progressive Multifocal leukoencephalopathy after natalizumab therapy for Crohn\u2019s disease.N Engl J Med online9 juin 2005.","DOI":"10.1056\/NEJMoa051586"},{"key":"R23","doi-asserted-by":"crossref","unstructured":"Feagan BG, Greenberg GR, Wild G,et al.Treatment of ulcerative colitis with a humanized antibody to the alpha4 beta7 integrin.N Engl J Med2005; 352 : 2499\u2013507.","DOI":"10.1056\/NEJMoa042982"},{"key":"R24","doi-asserted-by":"crossref","unstructured":"Osbourn J, Groves M, Vaughan T. From rodent reagents to human therapeutics using antibody guided selection.Methods2005; 36 : 61\u20138.","DOI":"10.1016\/j.ymeth.2005.01.006"},{"key":"R25","doi-asserted-by":"crossref","unstructured":"Jespers LS, Roberts A, Mahler SM,et al.Guiding the selection of human antibodies from phage display repertoires to a single epitope of an antigen.Biotechnology (NY)1994; 12 : 899\u2013903.","DOI":"10.1038\/nbt0994-899"},{"key":"R26","doi-asserted-by":"crossref","unstructured":"Wu H, Dall\u2019Acqua WF. Humanized antibodies and their applications.Methods2005; 36 : 1\u20132.","DOI":"10.1016\/j.ymeth.2005.02.001"},{"key":"R27","doi-asserted-by":"crossref","unstructured":"Anderson PJ. Tumor necrosis factor inhibitors : clinical implications of their different immunogenicity profiles.Semin Arthritis Rheum2005; 34 : 19\u201322.","DOI":"10.1016\/j.semarthrit.2005.01.005"},{"key":"R28","unstructured":"Ritter G, Cohen LS, Williams C Jr,et al.Serological analysis of human anti-human antibody responses in colon cancer patients treated with repeated doses of humanized monoclonal antibody A33.Cancer Res2001; 61 : 6851\u20139."},{"key":"R29","doi-asserted-by":"crossref","unstructured":"Kuus-Reichel K, Grauer LS, Karavodin LM,et al.Will immunogenicity limit the use, efficacy, and future development of therapeutic monoclonal antibodies ?Clin Diagn Lab Immunol1994; 1 : 365\u201372.","DOI":"10.1128\/CDLI.1.4.365-372.1994"},{"key":"R30","doi-asserted-by":"crossref","unstructured":"DeNardo GL, Bradt BM, Mirick GR, DeNardo SJ. Human antiglobulin response to foreign antibodies : therapeutic benefit ?Cancer Immunol Immunother2003; 52 : 309\u201316.","DOI":"10.1007\/s00262-002-0350-y"},{"key":"R31","unstructured":"Mirick GR, Bradt BM, Denardo SJ, Denardo GL. A review of human anti-globulin antibody (HAGA, HAMA, HACA, HAHA) responses to monoclonal antibodies. Not four letter words.Q J Nucl Med Mol Imaging2004; 48 : 251\u20137."},{"key":"R32","doi-asserted-by":"crossref","unstructured":"Kimball JA, Norman DJ, Shield CF,et al.The OKT3 antibody response study : a multicentre study of human anti-mouse antibody (HAMA) production following OKT3 use in solid organ transplantation.Transpl Immunol1995; 3 : 212\u201321.","DOI":"10.1016\/0966-3274(95)80027-1"},{"key":"R33","doi-asserted-by":"crossref","unstructured":"Gura T. Therapeutic antibodies : magic bullets hit the target.Nature2002; 417 : 584\u20136.","DOI":"10.1038\/417584a"},{"key":"R34","doi-asserted-by":"crossref","unstructured":"Reichert JM. Monoclonal antibodies in the clinic.Nat Biotechnol 2001; 19 : 819\u201322.","DOI":"10.1038\/nbt0901-819"},{"key":"R35","doi-asserted-by":"crossref","unstructured":"Featherstone J, Griffiths S. From the analyst\u2019s couch. Drugs that target angiogenesis.Nat Rev Drug Discov2002; 1 : 413\u20134.","DOI":"10.1038\/nrd824"}],"container-title":["m\u00e9decine\/sciences"],"original-title":[],"link":[{"URL":"http:\/\/www.medecinesciences.org\/10.1051\/medsci\/200521121054\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,18]],"date-time":"2021-12-18T02:08:54Z","timestamp":1639793334000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.medecinesciences.org\/10.1051\/medsci\/200521121054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,12]]},"references-count":35,"journal-issue":{"issue":"12"},"alternative-id":["medsci20052112p1054"],"URL":"https:\/\/doi.org\/10.1051\/medsci\/200521121054","relation":{},"ISSN":["0767-0974","1958-5381"],"issn-type":[{"value":"0767-0974","type":"print"},{"value":"1958-5381","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,12]]}}}